前列腺癌患者中,11C-胆碱PET检出的可疑亚厘米盆腔及腹膜后淋巴结CT引导经皮活检的安全性与有效性
回顾性研究纳入269例前列腺癌患者,比较CT引导活检<1 cm与≥1 cm可疑淋巴结的诊断效能与并发症。两组诊断率无显著差异(89.7% vs 92.9%,p=.40),<1 cm组恶性率较低(44.9% vs 63.7%,p=.003),并发症率无显著差异。结论支持对11C-胆碱PET检出的亚厘米淋巴结行CT引导活检的安全性和有效性。
要点
- <1 cm与≥1 cm淋巴结诊断率无显著差异(89.7% vs 92.9%,p=.40)。
- <1 cm淋巴结恶性率低于≥1 cm淋巴结(44.9% vs 63.7%,p=.003)。
- 两组轻微及严重并发症率均无显著差异(12.8% vs 7.1%,p=.16;0.6% vs 2.7%,p=.31)。
核心结论
- 研究结果支持对前列腺癌患者中11C-胆碱PET检出的可疑亚厘米盆腔及腹膜后淋巴结行CT引导活检的安全性和有效性。
研究设计与样本
- 回顾性研究纳入2012年6月1日至2020年3月20日期间269例前列腺癌患者,均因PSA升高或已知复发/转移性疾病行11C-胆碱PET/CT或PET/MRI后对可疑盆腔或腹膜后淋巴结行CT引导经皮活检。
诊断标准与关键数值
- 淋巴结<1 cm组(范围3-9 mm)与≥1 cm组(范围10-35 mm)诊断率分别为89.7% vs 92.9%(p=.40),无显著差异。
- 淋巴结<1 cm组与≥1 cm组恶性率分别为44.9% vs 63.7%(p=.003),<1 cm组较低。
- 盆腔或腹膜后各解剖部位内,<1 cm与≥1 cm淋巴结诊断率均无显著差异(所有p>.05)。
- 4 mm淋巴结诊断率和恶性率分别为100.0%和40.0%,5 mm淋巴结分别为95.5%和45.5%。
- 唯一活检的3 mm淋巴结标本无诊断结果。
临床应用与阅片要点
- 对11C-胆碱PET检出而形态学正常的小淋巴结,CT引导活检可获得与≥1 cm淋巴结相当的诊断率。
- 亚厘米淋巴结恶性率较低,活检结果阴性时需结合PET表现综合判断。
- CT引导活检的轻微和严重并发症率在亚厘米与≥1 cm淋巴结间无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. In patients with prostate cancer, PET using targeted radiotracers can identify increased activity in small morphologically normal lymph nodes, facilitating earlier detection of metastatic disease. OBJECTIVE. The purpose of this article was to assess the efficacy and safety of CT-guided biopsy of suspicious pelvic and retroperitoneal lymph nodes measuring smaller than 1 cm detected by 11C-choline PET in patients with prostate cancer, with comparison with nodes measuring 1 cm or larger. METHODS. This retrospective study included patients with prostate cancer who underwent CT-guided percutaneous biopsy of suspicious pelvic or retroperitoneal lymph nodes detected by 11C-choline PET/CT or PET/MRI (performed because of a rising or elevated PSA level or known recurrent or metastatic disease) between June 1, 2012, and March 20, 2020. Patient, lymph node, and procedural characteristics, as well as biopsy outcomes and complications, were recorded. Biopsies of lymph nodes measuring smaller than 1 cm and of lymph nodes measuring 1 cm and larger were compared. RESULTS. A total of 269 patients (mean age, 68.7 ± 6.8 [SD] years) were included. A total of 156 patients underwent biopsy of lymph nodes measuring smaller than 1 cm (range, 3-9 mm); 113 patients underwent biopsy of lymph nodes measuring 1 cm or larger (range, 10-35 mm). Lymph nodes smaller than 1 cm and lymph nodes 1 cm and larger showed no significant difference in diagnostic yield (89.7% vs 92.9%; p = .40). Diagnostic yield was not significantly different between nodes smaller than 1 cm and nodes 1 cm and larger for any individual anatomic location within the pelvis or retroperitoneum (all p > .05). Malignant yield was lower for nodes smaller than 1 cm than for nodes 1 cm and larger (44.9% vs 63.7%; p = .003). The single biopsied 3-mm node had a nondiagnostic specimen. Diagnostic yield and malignant yield were 100.0% and 40.0%, respectively, for 4-mm nodes, and 95.5% and 45.5%, respectively, for 5-mm nodes. Patients with nodes smaller than 1 cm and nodes 1 cm and larger showed no significant difference in minor (12.8% vs 7.1%; p = .16) or major (0.6% vs 2.7%; p = .31) complication rate. CONCLUSION. The findings support the safety and efficacy of CT-guided biopsy of suspicious subcentimeter pelvic and retroperitoneal lymph nodes detected on 11C-choline PET in patients with prostate cancer. CLINICAL IMPACT. Earlier diagnosis of metastatic lymphadenopathy will impact prognostic assessment and management decisions in patients with recurrent prostate cancer.
引用
- Kapplinger JD, Lima LMF, Packard AT, et al. Safety and Efficacy of CT-Guided Percutaneous Biopsy of Suspicious Subcentimeter Pelvic and Retroperitoneal Lymph Nodes Detected by 11C-Choline PET in Patients With Prostate Cancer. AJR Am J Roentgenol. 2022. PMID: 36475814. doi:10.2214/AJR.22.28321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。